Hims & Hers shares rise as company adds new weight-loss medications to platform

Hims & Hers shares rise as company adds new weight-loss medications to platform


The Hims app arranged on a smartphone in New York on Feb. 12, 2025.

Gabby Jones | Bloomberg | Getty Images

Hims & Hers Health shares rose more than 5% on Tuesday after the company announced patients can access Eli Lilly‘s weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic injection liraglutide, through its platform.

Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in popularity in recent years. Hims & Hers launched a weight loss program in late 2023, but its GLP-1 offerings have evolved as the company has contended with a volatile supply and regulatory environment.

Lilly’s weekly injections Zepbound and Mounjaro will cost patients $1,899 a month, according to the Hims & Hers website. The generic liraglutide will cost $299 a month, but it requires a daily injection and can be less effective than other GLP-1 medications.

“As we look ahead, we plan to continue to expand our weight loss offering to deliver an even more holistic, personalized experience,” Dr. Craig Primack, senior vice president of weight loss at Hims & Hers, wrote in a blog post.

In May, Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk’s GLP-1 weight loss medications Ozempic and Wegovy. The offering was immensely popular and helped generate more than $225 million in revenue for the company in 2024.

But compounded drugs can traditionally only be mass produced when the branded medications treatments are in shortage. The U.S. Food and Drug Administration announced in February that the shortage of semaglutide injections products had been resolved.

That meant Hims & Hers had to largely stop offering the compounded medications, though some consumers may still be able to access personalized doses if it’s clinically applicable. 

During the company’s quarterly call with investors in February, Hims & Hers said its weight loss offerings will primarily consist of its oral medications and liraglutide. The company said it expects its weight loss offerings to generate at least $725 million in annual revenue, excluding contributions from compounded semaglutide.

But the company is still lobbying for compounded medications. A pop up on Hims & Hers’ website, which was viewed by CNBC, encourages users to “use your voice” and urge Congress and the FDA to preserve access to compounded treatments.

With Tuesday’s rally, Hims and Hers shares are up about 27% in 2025 after soaring 172% last year.

WATCH: Hims & Hers shares tumble over concerns around weight-loss business

Hims & Hers shares tumble over concerns around weight-loss business



Source

‘Cyber plague’: Experts warn of growing infostealer threat after billions of login details exposed
Technology

‘Cyber plague’: Experts warn of growing infostealer threat after billions of login details exposed

“Someone, somewhere is having data exfiltrated from their machines as we speak,” says Volodymyr Diachenko, co-founder of the cybersecurity consultancy SecurityDiscovery. Sarayut Thaneerat | Moment | Getty Images Cybercriminals have intensified their efforts to steal and sell online passwords, experts warn. The alarm comes after the discovery of online datasets containing billions of exposed account […]

Read More
Adopt or die? How Southeast Asian small businesses are using AI to stay competitive
Technology

Adopt or die? How Southeast Asian small businesses are using AI to stay competitive

ASEAN member nations’ flags outside the Pullman Hotel, the venue for the ASEAN Foreign Ministers’ retreat meeting in Luang Prabang, Laos, in January 2024. Tang Chhin Sothytang Chhin Sothy | Afp | Getty Images The U.S. and China are usually top of mind when it comes to artificial intelligence and generative AI. But Southeast Asia’s […]

Read More
Meta wins AI copyright case, but judge says others could bring lawsuits
Technology

Meta wins AI copyright case, but judge says others could bring lawsuits

Meta CEO Mark Zuckerberg makes a keynote speech during the Meta Connect annual event, at the company’s headquarters in Menlo Park, California, on Sept. 25, 2024. Manuel Orbegozo | Reuters Meta on Wednesday prevailed against a group of 13 authors in a major copyright case involving the company’s Llama artificial intelligence model, but the judge […]

Read More